[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 451
Citations 0
Comment & Response
August 2015

Abuse-Deterrent Formulations of Prescription Opioids

Author Affiliations
  • 1Department of Anesthesia, Louisiana State University Health Science Center, New Orleans
  • 2Department of Anesthesiology, University of Michigan Health System, Ann Arbor
JAMA Psychiatry. 2015;72(8):849-850. doi:10.1001/jamapsychiatry.2015.0721

To the Editor It is with interest that we read the article “Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin” published in JAMA Psychiatry.1 Through their survey study, Cicero and Ellis1 concluded that abuse-deterrent formulations (ADFs) can have the intended purpose of curtailing abuse, but only with limited effectiveness, and efforts to reduce opioid supply alone with ADF technology will not mitigate the opioid abuse program in the United States.

First Page Preview View Large
First page PDF preview
First page PDF preview